Substantially altered expression pattern of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure.
Animal studies suggest that the endocannabinoid system (ECS) plays a role in the regulation of myocardial contractility and in the pathogenesis of heart failure. The current study aimed to proof the existence of endocannabinoid receptors on human ventricular myocardium and to determine whether human chronic heart failure (CHF) is associated with changes in endocannabinoid receptor expression and distribution. Expression of cannabinoid receptor 1 (CB1) and cannabinoid receptor (CB2) on human heart was assessed by means of real-time PCR and immunohistochemistry. On healthy human left ventricular myocardium, mRNA transcripts of CB1 and CB2 receptors were expressed in an almost equal proportion. In patients with CHF, mRNA expression of CB1 receptors was shown to be downregulated 0.7-fold (0.7.+/-0.15, n=12, p<0.01), whereas expression of CB2 receptors was upregulated more than 11-fold (11.6+/-4.5; n=12; p<0.005). Corresponding results were obtained by immunohistochemistry. Blood levels of endocannabinoids were significantly elevated (anandamide 3.5-fold (p<0.001); 2-AG 7-fold (p=0.02)) in patients with CHF, as compared to healthy volunteers. Both CB1 and CB2 receptors are present on healthy human left ventricular myocardium in a balanced distribution. Patients suffering from CHF exhibit a shift of the CB1-CB2 receptor ratio towards expression of CB2 receptors combined with significantly elevated peripheral blood levels of endocannabinoids indicating an activation of the ECS. These results might open up new perspectives regarding the role of endocannabinoid signalling in CHF and its potential as a target for pharmacological modulation.
Weis
Florian
F
Department of Anesthesiology, Ludwig-Maximilians University, Munich, Germany.
Beiras-Fernandez
Andres
A
Sodian
Ralf
R
Kaczmarek
Ingo
I
Reichart
Bruno
B
Beiras
Andres
A
Schelling
Gustav
G
Kreth
Simone
S
D000328:Adult; D001095:Arachidonic Acids / Q000097:blood; D063385:Cannabinoid Receptor Modulators / Q000097:blood / Q000378:metabolism*; D016022:Case-Control Studies; D063388:Endocannabinoids; D005786:Gene Expression Regulation; D005989:Glycerides / Q000097:blood; D006333:Heart Failure / Q000378:metabolism*; D006352:Heart Ventricles / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008875:Middle Aged; D009206:Myocardium / Q000473:pathology; D053284:Polyunsaturated Alkamides / Q000097:blood; D043884:Receptor, Cannabinoid, CB1 / Q000097:blood; D043885:Receptor, Cannabinoid, CB2 / Q000097:blood*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction
D001095:Arachidonic Acids; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D005989:Glycerides; D053284:Polyunsaturated Alkamides; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; C094503:glyceryl 2-arachidonate; C078814:anandamide